Moderna (MRNA) Q3 FY25 earnings call

Moderna delivered a mixed third quarter, marked by significant progress in cost reduction and strong uptake of its new COVID vaccine, mNEXSPIKE, which now leads its franchise. Despite a net loss and the discontinuation of its CMV program, the company is ahead of its cash cost reduction targets and has increased its year-end cash balance projection. Management remains committed to achieving cash breakeven by 2028 through continued financial discipline and pipeline advancement.